Table 1.
Baseline clinical features in patients with or without CI-AKI
| Variables | Total (n=350) | CI-AKI (+) (n=46) | CI-AKI (–) (n=304) | P |
|---|---|---|---|---|
| Demographics | ||||
| Age, years | 79.23±3.65 | 79.85±4.38 | 79.13±3.53 | 0.22 |
| Females, n, % | 93 (26.6) | 14 (30.4) | 79 (26.0) | 0.52 |
| BMI, kg/m2 | 23.54±3.26 | 23.84±4.15 | 23.51±3.16 | 0.64 |
| Heart failure at admission, n, % | 102 (29.1) | 25 (54.3) | 77 (25.4) | <0.001 |
| MI, n, % | 133 (38.0) | 33 (71.7) | 100 (32.9) | <0.001 |
| Medical history | ||||
| Hypertension, n, % | 271 (77.4) | 36 (78.3) | 235 (77.3) | 0.88 |
| Diabetes mellitus, n, % | 144 (41.1) | 22 (47.8) | 122 (40.1) | 0.32 |
| Smoking, n, % | 133 (38.0) | 19 (41.3) | 114 (38.1) | 0.69 |
| Prior MI, n, % | 63 (18.0) | 10 (21.7) | 53 (17.4) | 0.48 |
| Prior PCI, n, % | 84 (24.0) | 7 (15.2) | 77 (25.4) | 0.13 |
| Prior CABG, n, % | 2 (0.6) | 0 (0) | 2 (0.7) | 0.58 |
| Laboratory parameters | ||||
| SCr, mg/dL | 1.00±0.33 | 0.96±0.32 | 1.01±0.33 | 0.32 |
| SCr>1.5 mg/dL, n, % | 25 (7.1) | 3 (6.5) | 22 (7.2) | 1.0 |
| Baseline RBC, 1012/L | 4.17±0.57 | 4.2±0.69 | 4.17±0.55 | 0.78 |
| Hemoglobin, g/L | 127.79±16.98 | 125.61±22.3 | 128.12±16.04 | 0.35 |
| Anemia, n, % | 179 (51.1) | 24 (52.2) | 155 (51.0) | 0.88 |
| LDL, mmol/L | 2.58±0.94 | 2.59±0.82 | 2.59±0.96 | 1.00 |
| TC, mmol/L | 4.10±1.09 | 4.01±0.92 | 4.11±1.11 | 0.55 |
| TG, mmol/L | 1.39±0.99 | 1.32±0.67 | 1.41±1.03 | 0.57 |
| HDL, mmol/L | 1.09±0.32 | 1.03±0.33 | 1.1±0.32 | 0.18 |
| Uric acid, µmol/L | 369.17±112.17 | 395.3±107.66 | 365.16±112.48 | 0.09 |
| LVEF, % | 56.42±7.71 | 49.83±9.41 | 57.5±6.84 | <.001 |
| fT3, pmol/L | 3.84±0.93 | 3.39±0.96 | 3.91±0.9 | <.001 |
| fT4, pmol/L | 16.76±3.44 | 17.12±3.31 | 16.7±3.46 | 0.45 |
| S-TSH, mIU/L | 1.90±0.87 | 1.65±0.95 | 1.93±0.86 | 0.09 |
| Low fT3, n, % | 68 (19.4) | 18 (39.1) | 50 (16.4) | <0.001 |
| Perioperative medications | ||||
| Antiplatelet, n, % | 342 (97.7) | 45 (97.8) | 297 (97.7) | 0.72 |
| ACEI/ARB, n, % | 282 (80.6) | 33 (71.7) | 249 (81.9) | 0.10 |
| Statin, n, % | 342 (97.7) | 45 (97.8) | 297 (97.7) | 0.96 |
| Procedural characteristics | ||||
| Number of diseased vessels, n | 2.42±0.82 | 2.63±0.64 | 2.39±0.84 | 0.06 |
| LM, n, % | 38 (10.8) | 5 (10.9) | 33 (10.8) | 1.00 |
| LAD, n, % | 267 (76.3) | 28 (93.3) | 239 (89.2) | 0.75 |
| LCX, n, % | 196 (56.0) | 22 (73.3) | 174 (64.9) | 0.36 |
| RCA, n, % | 213 (60.8) | 24 (80.0) | 189 (70.5) | 0.28 |
| Stent length, mm | 40.10±23.82 | 43.42±22.48 | 39.57±24.02 | 0.31 |
| Number of stents, n | 1.53±0.79 | 1.64±0.77 | 1.52±0.79 | 0.32 |
| Perioperative hypotension, n, % | 24 (6.9) | 11 (23.9) | 13 (4.3) | <0.001 |
| Contrast volume, mL | 215.37±58.96 | 214.09±59.19 | 215.57±59.03 | 0.88 |
| Contrast volume>150 mL, n, % | 309 (88.3) | 40 (86.9) | 269 (88.5) | 0.76 |
Data are presented as the mean±standard deviations or as numbers and percentages.
CI-AKI - contrast-induced acute kidney injury; BMI - body mass index; MI - myocardial infarction; PCI - percutaneous coronary intervention; CABG - coronary artery bypass grafting; SCr - serum creatinine; RBC - red blood cell; LDL - low-density lipoprotein; TC - total cholesterol; TG - triglyceride; HDL - high-density lipoprotein; LVEF - left ventricular ejection fraction; fT3 - free triiodothyronine; fT4 - free thyroxine; S-TSH - sensitive thyroid-stimulating hormone; ACEI/ARB - angiotensin-converting enzyme inhibitor/angiotensin receptor blocker; LM - left main; LAD - left anterior descending branch; LCX - left circumflex branch; RCA - right coronary artery